Heparin, Low-Molecular-WeightAnticoagulantsDalteparinEnoxaparinNadroparinVenous ThrombosisHeparinVenous ThromboembolismFactor XaThromboembolismHemorrhageStockings, CompressionFibrinolytic AgentsPulmonary EmbolismAcenocoumarolWhole Blood Coagulation TimeHeparin AntagonistsAntithrombin ProteinsWarfarinBlood CoagulationInjections, SubcutaneousPartial Thromboplastin TimeHeparinoidsPlatelet Factor 4Pregnancy Complications, HematologicThrombosisIntermittent Pneumatic Compression DevicesThrombophiliaPolysaccharidesThrombophlebitisAntithrombinsThrombocytopeniaPregnancy Complications, CardiovascularTreatment OutcomeAntithrombin IIIAspirinPostoperative ComplicationsHeparin Cofactor IIVena Cava, InferiorInternational Normalized RatioRecurrencePlatelet Aggregation InhibitorsBlood Coagulation TestsJugular VeinsVitamin KDermatan SulfateOrthopedic ProceduresAdministration, OralBiological AvailabilityFibrin Fibrinogen Degradation ProductsProthrombinRenal InsufficiencyTime FactorsChemistry, PharmaceuticalDrug CarriersHydrogelsRenal DialysisAmbulatory CareDose-Response Relationship, DrugUltrasonography, Doppler, DuplexRandomized Controlled Trials as TopicPractice Guidelines as TopicRats, Sprague-DawleyRisk AssessmentDrug CostsIntraoperative CareRisk FactorsThrombinArthroplasty, Replacement, KneeProspective StudiesNeoplasmsDrug Therapy, CombinationPregnancy OutcomePregnancyAerosolsDrug Delivery SystemsArthroplasty, Replacement, HipPlatelet ActivationP-SelectinThromboplastinDrug Administration ScheduleIntestinal AbsorptionRetrospective StudiesParticle SizeAcute DiseaseVascular PatencyLegEvidence-Based MedicineInfusions, IntravenousPolyethylene GlycolsDisease Models, AnimalCost-Benefit AnalysisResearch DesignChi-Square DistributionRisk